Heron Therapeutics, Inc. (HRTX) 10-Year Financial Performance & Capital Metrics

HRTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutHeron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Show more

Revenue $144M +13.6%
EBITDA -$9M +91.6%
Net Income -$14M +87.7%
EPS (Diluted) -0.09 +88.9%
Gross Margin 73.21% +50.2%
EBITDA Margin -6.26% +92.6%
Operating Margin -7.99% +90.8%
Net Margin -9.41% +89.2%
ROE -
ROIC -7.35% +87.9%
Debt/Equity -
Interest Coverage -1.91 +93.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 10.4% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-0.23%

3Y18.67%

TTM12.6%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM51.45%

EPS CAGR

10Y-

5Y-

3Y-

TTM58.78%

ROCE

10Y Avg-103.4%

5Y Avg-64.77%

3Y Avg-55.26%

Latest-8.1%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	1.28M	30.77M	77.47M	145.97M	88.64M	86.35M	107.67M	127.04M	144.28M
Revenue Growth %	-	-	23.06%	1.52%	0.88%	-0.39%	-0.03%	0.25%	0.18%	0.14%
Cost of Goods Sold+	734K	35K	4.59M	27.51M	61.62M	36.19M	46.02M	54.87M	65.11M	38.65M
COGS % of Revenue	-	0.03%	0.15%	0.36%	0.42%	0.41%	0.53%	0.51%	0.51%	0.27%
Gross Profit+	-734K	1.24M	26.18M	49.96M	84.35M	52.45M	40.33M	52.8M	61.94M	105.64M
Gross Margin %	-	0.97%	0.85%	0.64%	0.58%	0.59%	0.47%	0.49%	0.49%	0.73%
Gross Profit Growth %	0.99%	2.69%	20.04%	0.91%	0.69%	-0.38%	-0.23%	0.31%	0.17%	0.71%
Operating Expenses+	96.92M	172.16M	220.74M	233.9M	295.04M	280.61M	258.15M	227.46M	172.55M	117.17M
OpEx % of Revenue	-	134.6%	7.17%	3.02%	2.02%	3.17%	2.99%	2.11%	1.36%	0.81%
Selling, General & Admin	35.74M	69.03M	82.16M	93.87M	127.66M	106.08M	127.33M	144.75M	119.82M	100.48M
SG&A % of Revenue	-	53.97%	2.67%	1.21%	0.87%	1.2%	1.47%	1.34%	0.94%	0.7%
Research & Development	61.18M	103.13M	138.58M	140.03M	167.38M	174.53M	130.82M	82.7M	39.13M	16.68M
R&D % of Revenue	-	80.63%	4.5%	1.81%	1.15%	1.97%	1.52%	0.77%	0.31%	0.12%
Other Operating Expenses	-666K	0	-38K	0	0	0	0	0	13.6M	0
Operating Income+	-96.92M	-170.91M	-194.56M	-183.94M	-210.69M	-228.16M	-217.83M	-174.66M	-110.61M	-11.53M
Operating Margin %	-	-133.63%	-6.32%	-2.37%	-1.44%	-2.57%	-2.52%	-1.62%	-0.87%	-0.08%
Operating Income Growth %	-0.3%	-0.76%	-0.14%	0.05%	-0.15%	-0.08%	0.05%	0.2%	0.37%	0.9%
EBITDA+	-96.19M	-169.82M	-193.03M	-182.42M	-208.65M	-225.32M	-214.81M	-171.77M	-107.72M	-9.04M
EBITDA Margin %	-	-132.77%	-6.27%	-2.35%	-1.43%	-2.54%	-2.49%	-1.6%	-0.85%	-0.06%
EBITDA Growth %	-0.3%	-0.77%	-0.14%	0.05%	-0.14%	-0.08%	0.05%	0.2%	0.37%	0.92%
D&A (Non-Cash Add-back)	734K	1.1M	1.53M	1.51M	2.04M	2.85M	3.02M	2.89M	2.9M	2.49M
EBIT	-96.92M	-170.48M	-193.55M	-176.17M	-203.28M	-225.38M	-218.27M	-179.55M	-106.69M	-7.55M
Net Interest Income+	0	-2.22M	-2.89M	3.29M	5.79M	1.73M	-1.98M	-836K	-504K	-2.48M
Interest Income	0	445K	1.05M	5.96M	7.26M	3.63M	433K	1.64M	3.36M	3.55M
Interest Expense	958K	2.66M	3.94M	2.67M	1.47M	1.9M	2.41M	2.47M	3.87M	6.03M
Other Income/Expense	-666K	-2.23M	-2.93M	5.1M	5.95M	885K	-2.85M	-7.37M	56K	-2.05M
Pretax Income+	-97.59M	-173.14M	-197.48M	-178.84M	-204.75M	-227.28M	-220.68M	-182.02M	-110.56M	-13.58M
Pretax Margin %	-	-135.37%	-6.42%	-2.31%	-1.4%	-2.56%	-2.56%	-1.69%	-0.87%	-0.09%
Income Tax+	-734K	-1.1M	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-97.59M	-173.14M	-197.48M	-178.84M	-204.75M	-227.28M	-220.68M	-182.02M	-110.56M	-13.58M
Net Margin %	-	-135.37%	-6.42%	-2.31%	-1.4%	-2.56%	-2.56%	-1.69%	-0.87%	-0.09%
Net Income Growth %	-0.28%	-0.77%	-0.14%	0.09%	-0.14%	-0.11%	0.03%	0.18%	0.39%	0.88%
Net Income (Continuing)	-97.59M	-173.14M	-197.48M	-178.84M	-204.75M	-227.28M	-220.68M	-182.02M	-110.56M	-13.58M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.95	-4.57	-3.65	-2.44	-2.50	-2.50	-2.24	-1.67	-0.80	-0.09
EPS Growth %	-0.03%	-0.55%	0.2%	0.33%	-0.02%	0%	0.1%	0.25%	0.52%	0.89%
EPS (Basic)	-2.95	-4.57	-3.65	-2.44	-2.50	-2.50	-2.24	-1.67	-0.80	-0.09
Diluted Shares Outstanding	33.08M	37.92M	54.04M	73.19M	81.78M	90.77M	98.47M	109M	138.13M	152.45M
Basic Shares Outstanding	33.08M	37.92M	54.04M	73.19M	81.78M	90.77M	98.47M	109M	138.13M	152.45M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	134.75M	62.14M	228.06M	447.25M	479.06M	314.2M	254.42M	205.44M	188.77M	209.01M
Cash & Short-Term Investments	131.17M	51.14M	172.38M	332.37M	390.97M	208.49M	157.58M	84.85M	80.41M	59.28M
Cash Only	75.18M	13.41M	144.58M	31.84M	71.9M	105.14M	90.54M	15.36M	28.68M	25.8M
Short-Term Investments	55.99M	37.72M	27.8M	300.54M	319.07M	103.35M	67.04M	69.49M	51.73M	33.48M
Accounts Receivable	0	1.96M	41.87M	64.65M	39.88M	41.85M	35.5M	52.05M	60.14M	78.88M
Days Sales Outstanding	-	559.34	496.77	304.59	99.72	172.33	150.06	176.44	172.77	199.55
Inventory	0	5.34M	10.11M	39.03M	24.97M	41.91M	48.38M	54.57M	42.11M	53.16M
Days Inventory Outstanding	-	55.69K	804.15	517.84	147.9	422.65	383.73	363	236.08	502.05
Other Current Assets	0	3.71M	3.7M	11.19M	0	0	0	13.96M	6.12M	17.69M
Total Non-Current Assets+	3.09M	5.34M	6.24M	14.93M	33.72M	39.36M	51.28M	45.52M	33.73M	24.13M
Property, Plant & Equipment	3.05M	5.08M	5.98M	14.68M	33.37M	39.01M	33.56M	29.8M	25.6M	17.65M
Fixed Asset Turnover	-	0.25x	5.14x	5.28x	4.37x	2.27x	2.57x	3.61x	4.96x	8.17x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	45K	263K	263K	254K	346K	346K	17.72M	15.71M	8.13M	6.48M
Total Assets+	137.84M	67.48M	234.31M	462.18M	512.78M	353.56M	305.71M	250.95M	222.51M	233.15M
Asset Turnover	-	0.02x	0.13x	0.17x	0.28x	0.25x	0.28x	0.43x	0.57x	0.62x
Asset Growth %	0.8%	-0.51%	2.47%	0.97%	0.11%	-0.31%	-0.14%	-0.18%	-0.11%	0.05%
Total Current Liabilities+	19.73M	38.73M	103.17M	92.02M	96.7M	102.5M	71.06M	82.36M	79.69M	91.46M
Accounts Payable	3.3M	6.81M	18.77M	16.86M	3.07M	629K	3.87M	3.59M	3.8M	11.71M
Days Payables Outstanding	1.64K	71.06K	1.49K	223.72	18.17	6.34	30.72	23.87	21.3	110.58
Short-Term Debt	2.22M	2.91M	28.68M	4.57M	5.62M	7.05M	0	0	0	0
Deferred Revenue (Current)	0	1000K	1000K	0	0	0	0	0	0	0
Other Current Liabilities	61K	3.59M	44.09M	780K	12.2M	11.91M	13.48M	11.28M	7.85M	7.96M
Current Ratio	6.83x	1.60x	2.21x	4.86x	4.95x	3.07x	3.58x	2.49x	2.37x	2.29x
Quick Ratio	6.83x	1.47x	2.11x	4.44x	4.70x	2.66x	2.90x	1.83x	1.84x	1.70x
Cash Conversion Cycle	-	-14.81K	-192.26	598.71	229.44	588.64	503.07	515.57	387.56	591.02
Total Non-Current Liabilities+	0	50M	0	0	12.24M	14.56M	157.08M	155.02M	176.79M	175.34M
Long-Term Debt	0	50M	0	0	0	0	149.08M	149.28M	173.75M	174.73M
Capital Lease Obligations	0	0	0	0	12.24M	14.56M	8M	5.5M	2.8M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	241K	241K	615K
Total Liabilities	19.73M	88.73M	103.17M	92.02M	108.95M	117.06M	228.14M	237.38M	256.48M	266.8M
Total Debt+	2.22M	52.91M	28.68M	4.57M	19.79M	24.61M	159.5M	157.48M	179.63M	177.76M
Net Debt	-72.96M	39.5M	-115.9M	-27.26M	-52.11M	-80.53M	68.95M	142.11M	150.95M	151.96M
Debt / Equity	0.02x	-	0.22x	0.01x	0.05x	0.10x	2.06x	11.60x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-101.17x	-64.16x	-49.42x	-68.84x	-143.13x	-120.02x	-90.39x	-70.60x	-28.60x	-1.91x
Total Equity+	118.11M	-21.25M	131.14M	370.16M	403.83M	236.49M	77.57M	13.57M	-33.97M	-33.65M
Equity Growth %	0.87%	-1.18%	7.17%	1.82%	0.09%	-0.41%	-0.67%	-0.83%	-3.5%	0.01%
Book Value per Share	3.57	-0.56	2.43	5.06	4.94	2.61	0.79	0.12	-0.25	-0.22
Total Shareholders' Equity	118.11M	-21.25M	131.14M	370.16M	403.83M	236.49M	77.57M	13.57M	-33.97M	-33.65M
Common Stock	361K	394K	646K	782K	903K	913K	1.02M	1.19M	1.5M	1.52M
Retained Earnings	-412.83M	-585.97M	-783.46M	-960.72M	-1.17B	-1.39B	-1.61B	-1.8B	-1.91B	-1.92B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-40K	-17K	-10K	-87K	85K	257K	-6K	-19K	13K	13K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-78.53M	-134.1M	-170.3M	-191.81M	-124.58M	-184.82M	-203.35M	-146.91M	-58.79M	-22.53M
Operating CF Margin %	-	-104.85%	-5.54%	-2.48%	-0.85%	-2.09%	-2.36%	-1.36%	-0.46%	-0.16%
Operating CF Growth %	-0.3%	-0.71%	-0.27%	-0.13%	0.35%	-0.48%	-0.1%	0.28%	0.6%	0.62%
Net Income	-97.59M	-173.14M	-197.48M	-178.84M	-204.75M	-227.28M	-220.68M	-182.02M	-110.56M	-13.58M
Depreciation & Amortization	734K	1.1M	1.53M	1.51M	2.04M	2.85M	3.02M	2.89M	2.9M	2.49M
Stock-Based Compensation	14.36M	25.96M	30.54M	33.37M	51.41M	50.22M	46.85M	42.98M	32.85M	12.96M
Deferred Taxes	-29K	283K	-239K	-3.31M	-3.57M	972K	1.63M	0	0	0
Other Non-Cash Items	624K	689K	773K	890K	1.05M	1.43M	904K	-251K	-773K	3.2M
Working Capital Changes	3.38M	11.02M	-5.42M	-45.42M	29.23M	-13.01M	-35.08M	-10.51M	16.79M	-27.6M
Change in Receivables	0	-1.96M	-39.91M	-22.78M	24.77M	-1.97M	6.35M	-16.55M	-8.09M	-18.74M
Change in Inventory	0	-5.34M	-4.77M	-29.12M	14.06M	-16.94M	-6.48M	-6.19M	12.46M	-11.05M
Change in Payables	751K	3.51M	11.96M	-1.91M	-14.11M	-2.23M	3.28M	-578K	15K	8.47M
Cash from Investing+	-56.96M	14.88M	7.74M	-278.55M	-21.78M	208.96M	32.73M	-3.32M	18M	18.71M
Capital Expenditures	-1.09M	-3.13M	-2.55M	-9.17M	-7.15M	-6.81M	-3.02M	-1.82M	-1.54M	-1.71M
CapEx % of Revenue	-	2.45%	0.08%	0.12%	0.05%	0.08%	0.03%	0.02%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	137.99M	57.45M	293.73M	357.61M	186.43M	9.11M	156.03M	75.06M	54.11M	940K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-79.61M	-137.23M	-172.85M	-200.98M	-131.73M	-191.63M	-206.38M	-148.74M	-60.33M	-24.23M
FCF Margin %	-	-107.3%	-5.62%	-2.59%	-0.9%	-2.16%	-2.39%	-1.38%	-0.47%	-0.17%
FCF Growth %	-0.29%	-0.72%	-0.26%	-0.16%	0.34%	-0.45%	-0.08%	0.28%	0.59%	0.6%
FCF per Share	-2.41	-3.62	-3.20	-2.75	-1.61	-2.11	-2.10	-1.36	-0.44	-0.16
FCF Conversion (FCF/Net Income)	0.80x	0.77x	0.86x	1.07x	0.61x	0.81x	0.92x	0.81x	0.53x	1.66x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-107.73%	-357.52%	-359.44%	-71.35%	-52.91%	-70.99%	-140.53%	-399.43%	-	-
Return on Invested Capital (ROIC)	-391.49%	-404.39%	-871.6%	-77.04%	-45.5%	-67.41%	-108.02%	-86.69%	-60.85%	-7.35%
Gross Margin	-	97.26%	85.09%	64.49%	57.79%	59.17%	46.7%	49.04%	48.75%	73.21%
Net Margin	-	-13537.37%	-641.87%	-230.84%	-140.27%	-256.41%	-255.58%	-169.05%	-87.02%	-9.41%
Debt / Equity	0.02x	-	0.22x	0.01x	0.05x	0.10x	2.06x	11.60x	-	-
Interest Coverage	-101.17x	-64.16x	-49.42x	-68.84x	-143.13x	-120.02x	-90.39x	-70.60x	-28.60x	-1.91x
FCF Conversion	0.80x	0.77x	0.86x	1.07x	0.61x	0.81x	0.92x	0.81x	0.53x	1.66x
Revenue Growth	-	-	2305.55%	151.81%	88.41%	-39.28%	-2.59%	24.7%	17.99%	13.57%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
C I N V A N T I	132.2M	87.8M	73.51M	87.25M	94.87M	100.08M
C I N V A N T I Growth	-	-33.59%	-16.28%	18.69%	8.74%	5.49%
Z Y N R E L E F	-	-	2.92M	10.2M	17.73M	25.55M
Z Y N R E L E F Growth	-	-	-	248.70%	73.86%	44.11%
S U S T O L	13.8M	800K	9.91M	10.23M	13.06M	14.14M
S U S T O L Growth	-	-94.20%	1139.38%	3.19%	27.62%	8.31%

Frequently Asked Questions

Growth & Financials

Heron Therapeutics, Inc. (HRTX) reported $155.1M in revenue for fiscal year 2024. This represents a 23909% increase from $0.6M in 2011.

Heron Therapeutics, Inc. (HRTX) grew revenue by 13.6% over the past year. This is steady growth.

Heron Therapeutics, Inc. (HRTX) reported a net loss of $13.6M for fiscal year 2024.

Dividend & Returns

Heron Therapeutics, Inc. (HRTX) had negative free cash flow of $31.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Heron Therapeutics, Inc. (HRTX) 10-Year Financial Performance & Capital Metrics

HRTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $144M +13.6%
EBITDA -$9M +91.6%
Net Income -$14M +87.7%
EPS (Diluted) -0.09 +88.9%
Gross Margin 73.21% +50.2%
EBITDA Margin -6.26% +92.6%
Operating Margin -7.99% +90.8%
Net Margin -9.41% +89.2%
ROE -
ROIC -7.35% +87.9%
Debt/Equity -
Interest Coverage -1.91 +93.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 10.4% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-0.23%

3Y18.67%

TTM12.6%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM51.45%

EPS CAGR

10Y-

5Y-

3Y-

TTM58.78%

ROCE

10Y Avg-103.4%

5Y Avg-64.77%

3Y Avg-55.26%

Latest-8.1%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	1.28M	30.77M	77.47M	145.97M	88.64M	86.35M	107.67M	127.04M	144.28M
Revenue Growth %	-	-	23.06%	1.52%	0.88%	-0.39%	-0.03%	0.25%	0.18%	0.14%
Cost of Goods Sold+	734K	35K	4.59M	27.51M	61.62M	36.19M	46.02M	54.87M	65.11M	38.65M
COGS % of Revenue	-	0.03%	0.15%	0.36%	0.42%	0.41%	0.53%	0.51%	0.51%	0.27%
Gross Profit+	-734K	1.24M	26.18M	49.96M	84.35M	52.45M	40.33M	52.8M	61.94M	105.64M
Gross Margin %	-	0.97%	0.85%	0.64%	0.58%	0.59%	0.47%	0.49%	0.49%	0.73%
Gross Profit Growth %	0.99%	2.69%	20.04%	0.91%	0.69%	-0.38%	-0.23%	0.31%	0.17%	0.71%
Operating Expenses+	96.92M	172.16M	220.74M	233.9M	295.04M	280.61M	258.15M	227.46M	172.55M	117.17M
OpEx % of Revenue	-	134.6%	7.17%	3.02%	2.02%	3.17%	2.99%	2.11%	1.36%	0.81%
Selling, General & Admin	35.74M	69.03M	82.16M	93.87M	127.66M	106.08M	127.33M	144.75M	119.82M	100.48M
SG&A % of Revenue	-	53.97%	2.67%	1.21%	0.87%	1.2%	1.47%	1.34%	0.94%	0.7%
Research & Development	61.18M	103.13M	138.58M	140.03M	167.38M	174.53M	130.82M	82.7M	39.13M	16.68M
R&D % of Revenue	-	80.63%	4.5%	1.81%	1.15%	1.97%	1.52%	0.77%	0.31%	0.12%
Other Operating Expenses	-666K	0	-38K	0	0	0	0	0	13.6M	0
Operating Income+	-96.92M	-170.91M	-194.56M	-183.94M	-210.69M	-228.16M	-217.83M	-174.66M	-110.61M	-11.53M
Operating Margin %	-	-133.63%	-6.32%	-2.37%	-1.44%	-2.57%	-2.52%	-1.62%	-0.87%	-0.08%
Operating Income Growth %	-0.3%	-0.76%	-0.14%	0.05%	-0.15%	-0.08%	0.05%	0.2%	0.37%	0.9%
EBITDA+	-96.19M	-169.82M	-193.03M	-182.42M	-208.65M	-225.32M	-214.81M	-171.77M	-107.72M	-9.04M
EBITDA Margin %	-	-132.77%	-6.27%	-2.35%	-1.43%	-2.54%	-2.49%	-1.6%	-0.85%	-0.06%
EBITDA Growth %	-0.3%	-0.77%	-0.14%	0.05%	-0.14%	-0.08%	0.05%	0.2%	0.37%	0.92%
D&A (Non-Cash Add-back)	734K	1.1M	1.53M	1.51M	2.04M	2.85M	3.02M	2.89M	2.9M	2.49M
EBIT	-96.92M	-170.48M	-193.55M	-176.17M	-203.28M	-225.38M	-218.27M	-179.55M	-106.69M	-7.55M
Net Interest Income+	0	-2.22M	-2.89M	3.29M	5.79M	1.73M	-1.98M	-836K	-504K	-2.48M
Interest Income	0	445K	1.05M	5.96M	7.26M	3.63M	433K	1.64M	3.36M	3.55M
Interest Expense	958K	2.66M	3.94M	2.67M	1.47M	1.9M	2.41M	2.47M	3.87M	6.03M
Other Income/Expense	-666K	-2.23M	-2.93M	5.1M	5.95M	885K	-2.85M	-7.37M	56K	-2.05M
Pretax Income+	-97.59M	-173.14M	-197.48M	-178.84M	-204.75M	-227.28M	-220.68M	-182.02M	-110.56M	-13.58M
Pretax Margin %	-	-135.37%	-6.42%	-2.31%	-1.4%	-2.56%	-2.56%	-1.69%	-0.87%	-0.09%
Income Tax+	-734K	-1.1M	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-97.59M	-173.14M	-197.48M	-178.84M	-204.75M	-227.28M	-220.68M	-182.02M	-110.56M	-13.58M
Net Margin %	-	-135.37%	-6.42%	-2.31%	-1.4%	-2.56%	-2.56%	-1.69%	-0.87%	-0.09%
Net Income Growth %	-0.28%	-0.77%	-0.14%	0.09%	-0.14%	-0.11%	0.03%	0.18%	0.39%	0.88%
Net Income (Continuing)	-97.59M	-173.14M	-197.48M	-178.84M	-204.75M	-227.28M	-220.68M	-182.02M	-110.56M	-13.58M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.95	-4.57	-3.65	-2.44	-2.50	-2.50	-2.24	-1.67	-0.80	-0.09
EPS Growth %	-0.03%	-0.55%	0.2%	0.33%	-0.02%	0%	0.1%	0.25%	0.52%	0.89%
EPS (Basic)	-2.95	-4.57	-3.65	-2.44	-2.50	-2.50	-2.24	-1.67	-0.80	-0.09
Diluted Shares Outstanding	33.08M	37.92M	54.04M	73.19M	81.78M	90.77M	98.47M	109M	138.13M	152.45M
Basic Shares Outstanding	33.08M	37.92M	54.04M	73.19M	81.78M	90.77M	98.47M	109M	138.13M	152.45M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	134.75M	62.14M	228.06M	447.25M	479.06M	314.2M	254.42M	205.44M	188.77M	209.01M
Cash & Short-Term Investments	131.17M	51.14M	172.38M	332.37M	390.97M	208.49M	157.58M	84.85M	80.41M	59.28M
Cash Only	75.18M	13.41M	144.58M	31.84M	71.9M	105.14M	90.54M	15.36M	28.68M	25.8M
Short-Term Investments	55.99M	37.72M	27.8M	300.54M	319.07M	103.35M	67.04M	69.49M	51.73M	33.48M
Accounts Receivable	0	1.96M	41.87M	64.65M	39.88M	41.85M	35.5M	52.05M	60.14M	78.88M
Days Sales Outstanding	-	559.34	496.77	304.59	99.72	172.33	150.06	176.44	172.77	199.55
Inventory	0	5.34M	10.11M	39.03M	24.97M	41.91M	48.38M	54.57M	42.11M	53.16M
Days Inventory Outstanding	-	55.69K	804.15	517.84	147.9	422.65	383.73	363	236.08	502.05
Other Current Assets	0	3.71M	3.7M	11.19M	0	0	0	13.96M	6.12M	17.69M
Total Non-Current Assets+	3.09M	5.34M	6.24M	14.93M	33.72M	39.36M	51.28M	45.52M	33.73M	24.13M
Property, Plant & Equipment	3.05M	5.08M	5.98M	14.68M	33.37M	39.01M	33.56M	29.8M	25.6M	17.65M
Fixed Asset Turnover	-	0.25x	5.14x	5.28x	4.37x	2.27x	2.57x	3.61x	4.96x	8.17x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	45K	263K	263K	254K	346K	346K	17.72M	15.71M	8.13M	6.48M
Total Assets+	137.84M	67.48M	234.31M	462.18M	512.78M	353.56M	305.71M	250.95M	222.51M	233.15M
Asset Turnover	-	0.02x	0.13x	0.17x	0.28x	0.25x	0.28x	0.43x	0.57x	0.62x
Asset Growth %	0.8%	-0.51%	2.47%	0.97%	0.11%	-0.31%	-0.14%	-0.18%	-0.11%	0.05%
Total Current Liabilities+	19.73M	38.73M	103.17M	92.02M	96.7M	102.5M	71.06M	82.36M	79.69M	91.46M
Accounts Payable	3.3M	6.81M	18.77M	16.86M	3.07M	629K	3.87M	3.59M	3.8M	11.71M
Days Payables Outstanding	1.64K	71.06K	1.49K	223.72	18.17	6.34	30.72	23.87	21.3	110.58
Short-Term Debt	2.22M	2.91M	28.68M	4.57M	5.62M	7.05M	0	0	0	0
Deferred Revenue (Current)	0	1000K	1000K	0	0	0	0	0	0	0
Other Current Liabilities	61K	3.59M	44.09M	780K	12.2M	11.91M	13.48M	11.28M	7.85M	7.96M
Current Ratio	6.83x	1.60x	2.21x	4.86x	4.95x	3.07x	3.58x	2.49x	2.37x	2.29x
Quick Ratio	6.83x	1.47x	2.11x	4.44x	4.70x	2.66x	2.90x	1.83x	1.84x	1.70x
Cash Conversion Cycle	-	-14.81K	-192.26	598.71	229.44	588.64	503.07	515.57	387.56	591.02
Total Non-Current Liabilities+	0	50M	0	0	12.24M	14.56M	157.08M	155.02M	176.79M	175.34M
Long-Term Debt	0	50M	0	0	0	0	149.08M	149.28M	173.75M	174.73M
Capital Lease Obligations	0	0	0	0	12.24M	14.56M	8M	5.5M	2.8M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	241K	241K	615K
Total Liabilities	19.73M	88.73M	103.17M	92.02M	108.95M	117.06M	228.14M	237.38M	256.48M	266.8M
Total Debt+	2.22M	52.91M	28.68M	4.57M	19.79M	24.61M	159.5M	157.48M	179.63M	177.76M
Net Debt	-72.96M	39.5M	-115.9M	-27.26M	-52.11M	-80.53M	68.95M	142.11M	150.95M	151.96M
Debt / Equity	0.02x	-	0.22x	0.01x	0.05x	0.10x	2.06x	11.60x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-101.17x	-64.16x	-49.42x	-68.84x	-143.13x	-120.02x	-90.39x	-70.60x	-28.60x	-1.91x
Total Equity+	118.11M	-21.25M	131.14M	370.16M	403.83M	236.49M	77.57M	13.57M	-33.97M	-33.65M
Equity Growth %	0.87%	-1.18%	7.17%	1.82%	0.09%	-0.41%	-0.67%	-0.83%	-3.5%	0.01%
Book Value per Share	3.57	-0.56	2.43	5.06	4.94	2.61	0.79	0.12	-0.25	-0.22
Total Shareholders' Equity	118.11M	-21.25M	131.14M	370.16M	403.83M	236.49M	77.57M	13.57M	-33.97M	-33.65M
Common Stock	361K	394K	646K	782K	903K	913K	1.02M	1.19M	1.5M	1.52M
Retained Earnings	-412.83M	-585.97M	-783.46M	-960.72M	-1.17B	-1.39B	-1.61B	-1.8B	-1.91B	-1.92B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-40K	-17K	-10K	-87K	85K	257K	-6K	-19K	13K	13K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-78.53M	-134.1M	-170.3M	-191.81M	-124.58M	-184.82M	-203.35M	-146.91M	-58.79M	-22.53M
Operating CF Margin %	-	-104.85%	-5.54%	-2.48%	-0.85%	-2.09%	-2.36%	-1.36%	-0.46%	-0.16%
Operating CF Growth %	-0.3%	-0.71%	-0.27%	-0.13%	0.35%	-0.48%	-0.1%	0.28%	0.6%	0.62%
Net Income	-97.59M	-173.14M	-197.48M	-178.84M	-204.75M	-227.28M	-220.68M	-182.02M	-110.56M	-13.58M
Depreciation & Amortization	734K	1.1M	1.53M	1.51M	2.04M	2.85M	3.02M	2.89M	2.9M	2.49M
Stock-Based Compensation	14.36M	25.96M	30.54M	33.37M	51.41M	50.22M	46.85M	42.98M	32.85M	12.96M
Deferred Taxes	-29K	283K	-239K	-3.31M	-3.57M	972K	1.63M	0	0	0
Other Non-Cash Items	624K	689K	773K	890K	1.05M	1.43M	904K	-251K	-773K	3.2M
Working Capital Changes	3.38M	11.02M	-5.42M	-45.42M	29.23M	-13.01M	-35.08M	-10.51M	16.79M	-27.6M
Change in Receivables	0	-1.96M	-39.91M	-22.78M	24.77M	-1.97M	6.35M	-16.55M	-8.09M	-18.74M
Change in Inventory	0	-5.34M	-4.77M	-29.12M	14.06M	-16.94M	-6.48M	-6.19M	12.46M	-11.05M
Change in Payables	751K	3.51M	11.96M	-1.91M	-14.11M	-2.23M	3.28M	-578K	15K	8.47M
Cash from Investing+	-56.96M	14.88M	7.74M	-278.55M	-21.78M	208.96M	32.73M	-3.32M	18M	18.71M
Capital Expenditures	-1.09M	-3.13M	-2.55M	-9.17M	-7.15M	-6.81M	-3.02M	-1.82M	-1.54M	-1.71M
CapEx % of Revenue	-	2.45%	0.08%	0.12%	0.05%	0.08%	0.03%	0.02%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	137.99M	57.45M	293.73M	357.61M	186.43M	9.11M	156.03M	75.06M	54.11M	940K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-79.61M	-137.23M	-172.85M	-200.98M	-131.73M	-191.63M	-206.38M	-148.74M	-60.33M	-24.23M
FCF Margin %	-	-107.3%	-5.62%	-2.59%	-0.9%	-2.16%	-2.39%	-1.38%	-0.47%	-0.17%
FCF Growth %	-0.29%	-0.72%	-0.26%	-0.16%	0.34%	-0.45%	-0.08%	0.28%	0.59%	0.6%
FCF per Share	-2.41	-3.62	-3.20	-2.75	-1.61	-2.11	-2.10	-1.36	-0.44	-0.16
FCF Conversion (FCF/Net Income)	0.80x	0.77x	0.86x	1.07x	0.61x	0.81x	0.92x	0.81x	0.53x	1.66x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-107.73%	-357.52%	-359.44%	-71.35%	-52.91%	-70.99%	-140.53%	-399.43%	-	-
Return on Invested Capital (ROIC)	-391.49%	-404.39%	-871.6%	-77.04%	-45.5%	-67.41%	-108.02%	-86.69%	-60.85%	-7.35%
Gross Margin	-	97.26%	85.09%	64.49%	57.79%	59.17%	46.7%	49.04%	48.75%	73.21%
Net Margin	-	-13537.37%	-641.87%	-230.84%	-140.27%	-256.41%	-255.58%	-169.05%	-87.02%	-9.41%
Debt / Equity	0.02x	-	0.22x	0.01x	0.05x	0.10x	2.06x	11.60x	-	-
Interest Coverage	-101.17x	-64.16x	-49.42x	-68.84x	-143.13x	-120.02x	-90.39x	-70.60x	-28.60x	-1.91x
FCF Conversion	0.80x	0.77x	0.86x	1.07x	0.61x	0.81x	0.92x	0.81x	0.53x	1.66x
Revenue Growth	-	-	2305.55%	151.81%	88.41%	-39.28%	-2.59%	24.7%	17.99%	13.57%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
C I N V A N T I	132.2M	87.8M	73.51M	87.25M	94.87M	100.08M
C I N V A N T I Growth	-	-33.59%	-16.28%	18.69%	8.74%	5.49%
Z Y N R E L E F	-	-	2.92M	10.2M	17.73M	25.55M
Z Y N R E L E F Growth	-	-	-	248.70%	73.86%	44.11%
S U S T O L	13.8M	800K	9.91M	10.23M	13.06M	14.14M
S U S T O L Growth	-	-94.20%	1139.38%	3.19%	27.62%	8.31%

Frequently Asked Questions

Growth & Financials

Heron Therapeutics, Inc. (HRTX) reported $155.1M in revenue for fiscal year 2024. This represents a 23909% increase from $0.6M in 2011.

Heron Therapeutics, Inc. (HRTX) grew revenue by 13.6% over the past year. This is steady growth.

Heron Therapeutics, Inc. (HRTX) reported a net loss of $13.6M for fiscal year 2024.

Dividend & Returns

Heron Therapeutics, Inc. (HRTX) had negative free cash flow of $31.1M in fiscal year 2024, likely due to heavy capital investments.